A volunteer in an AstraZeneca COVID-19 vaccine clinical trial has died, but testing will continue. The company’s shares fell 1.8%

A volunteer died in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford. The university previously confirmed the person in Brazil, but did not provide other personal data, Reuters reports.

According to Oxford, testing will continue as “there were no concerns about the safety of the clinical trial.” The Federal University of Sao Paulo, which helps coordinate phase 3 clinical trials in Brazil, said an independent review committee also recommended more tests.

“Everything is going as expected, without any evidence of serious complications from the vaccine involving any of the participating volunteers,” the Brazilian university said in a statement.

To date, 8,000 of the 10,000 recruited volunteers have received the first dose in six cities in Brazil and some have received the second dose, a university spokesman said.

CNN Brazil reports that the volunteer was a 28-year-old man living in Rio de Janeiro. He died of complications from COVID-19.

Anvisa did not provide further details, citing the medical confidentiality of those involved in the studies.

AstraZeneca shares fell 1.8%.

The Brazilian federal government plans to buy the vaccine in the UK and produce it at the FioCruz biomedical research center in Rio de Janeiro, while the Sao Paulo research center is testing a vaccine from competition from Sinovac Biotech Ltd in China.

Brazil has the second highest number of coronavirus deaths after the United States, with more than 154,000 deaths. It has the third highest number of COVID-19 cases, of more than 5.2 million infected, ranking in the top of the most affected countries after the United States and India.